Related Experiment Video
Updated: Feb 24, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C Wei1, Jacob H Levine2, Alexandria P Cogdill3
1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Immune-checkpoint blockade is able to achieve durable responses in a subset of patients; however, we lack a satisfying comprehension of the underlying mechanisms of anti-CTLA-4- and anti-PD-1-induced tumor rejection. To address these issues, we utilized mass cytometry to comprehensively profile the effects of checkpoint blockade on tumor immune infiltrates in human melanoma and murine tumor models. These analyses reveal a spectrum of tumor-infiltrating T cell populations that are highly similar between tumor models and indicate that checkpoint blockade targets only specific subsets of tumor-infiltrating T cell populations. Anti-PD-1 predominantly induces the expansion of specific tumor-infiltrating exhausted-like CD8 T cell subsets. In contrast, anti-CTLA-4 induces the expansion of an ICOS+ Th1-like CD4 effector population in addition to engaging specific subsets of exhausted-like CD8 T cells. Thus, our findings indicate that anti-CTLA-4 and anti-PD-1 checkpoint-blockade-induced immune responses are driven by distinct cellular mechanisms.
Insights
Immune checkpoint blockade, including anti-CTLA-4 and anti-PD-1 therapies, targets specific T cell subsets in tumors. These therapies activate distinct immune cell mechanisms, leading to tumor rejection through different pathways.
Area of Science:
- Immunology
- Cancer Research
- T cell biology
Background:
- Immune checkpoint blockade (ICB) offers durable responses in some cancer patients.
- Understanding the mechanisms of anti-CTLA-4 and anti-PD-1 in tumor rejection is limited.
Purpose of the Study:
- To comprehensively profile the effects of ICB on tumor immune infiltrates.
- To elucidate the distinct cellular mechanisms of anti-CTLA-4 and anti-PD-1 therapies.
Main Methods:
- Mass cytometry was used to analyze tumor immune infiltrates.
- Human melanoma and murine tumor models were studied.
Main Results:
- ICB targets specific subsets of tumor-infiltrating T cells.
- Anti-PD-1 expands exhausted-like CD8 T cell subsets.
- Anti-CTLA-4 expands ICOS+ Th1-like CD4 effector cells and specific exhausted-like CD8 T cells.
Conclusions:
- Anti-CTLA-4 and anti-PD-1 engage distinct cellular mechanisms for tumor rejection.
- Findings provide insights into ICB response heterogeneity.
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Inhibition of Cdk Activity
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The Intrinsic Apoptotic Pathway

